Publication:
Setting Our Sights on Infectious Diseases

Simple item page
dc.contributor.authorManu De Ryckeren_US
dc.contributor.authorDavid Hornen_US
dc.contributor.authorBree Aldridgeen_US
dc.contributor.authorRichard K. Amewuen_US
dc.contributor.authorClifton E. Barryen_US
dc.contributor.authorFrederick S. Buckneren_US
dc.contributor.authorSarah Cooken_US
dc.contributor.authorMichael A.J. Fergusonen_US
dc.contributor.authorNathalie Gobeauen_US
dc.contributor.authorJennifer Herrmannen_US
dc.contributor.authorPaul Herrlingen_US
dc.contributor.authorWilliam Hopeen_US
dc.contributor.authorJennifer Keiseren_US
dc.contributor.authorMaria Jose Lafuente-Monasterioen_US
dc.contributor.authorPaul D. Leesonen_US
dc.contributor.authorDidier Leroyen_US
dc.contributor.authorUjjini H. Manjunathaen_US
dc.contributor.authorJames McCarthyen_US
dc.contributor.authorTimothy J. Milesen_US
dc.contributor.authorValerie Mizrahien_US
dc.contributor.authorOlena Moshynetsen_US
dc.contributor.authorJacquin Nilesen_US
dc.contributor.authorJohn P. Overingtonen_US
dc.contributor.authorJohn Pottageen_US
dc.contributor.authorSrinivasa P.S. Raoen_US
dc.contributor.authorKevin D. Readen_US
dc.contributor.authorIsabela Ribeiroen_US
dc.contributor.authorLynn L. Silveren_US
dc.contributor.authorJen Southernen_US
dc.contributor.authorThomas Spangenbergen_US
dc.contributor.authorShyam Sundaren_US
dc.contributor.authorCaitlin Tayloren_US
dc.contributor.authorWes Van Voorhisen_US
dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.authorSusan Wyllieen_US
dc.contributor.authorPaul G. Wyatten_US
dc.contributor.authorIan H. Gilberten_US
dc.contributor.otherLancaster Institute for the Contemporary Artsen_US
dc.contributor.otherViiV Healthcareen_US
dc.contributor.otherHelmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS)en_US
dc.contributor.otherGlaxoSmithKline plc, Spainen_US
dc.contributor.otherInstitute of Molecular Biology and Genetics National Academy of Sciences of Ukraineen_US
dc.contributor.otherBanaras Hindu University, Institute of Medical Sciencesen_US
dc.contributor.otherQIMR Berghofer Medical Research Instituteen_US
dc.contributor.otherUniversitat Baselen_US
dc.contributor.otherSwiss Tropical and Public Health Institute (Swiss TPH)en_US
dc.contributor.otherMassachusetts Institute of Technologyen_US
dc.contributor.otherUniversity of Liverpoolen_US
dc.contributor.otherMerck KGaAen_US
dc.contributor.otherUniversity of Ghanaen_US
dc.contributor.otherNational Institute of Allergy and Infectious Diseasesen_US
dc.contributor.otherTufts University School of Medicineen_US
dc.contributor.otherUniversity of Washington, Seattleen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherHelmholtz Centre for Infection Research (HZI)en_US
dc.contributor.otherUniversity of Dundeeen_US
dc.contributor.otherNovartis Institutes for BioMedical Research, Inc.en_US
dc.contributor.otherUniversity of Glasgowen_US
dc.contributor.otherUniversity of Cape Townen_US
dc.contributor.otherPaul Leeson Consulting Ltd.en_US
dc.contributor.otherLL Silver Consultingen_US
dc.contributor.otherMedicines for Malaria Ventureen_US
dc.contributor.otherDrugs for Neglected Diseases Initiativeen_US
dc.contributor.otherMedicines Discovery Catapulten_US
dc.contributor.otherIndependent Consultanten_US
dc.date.accessioned2020-03-26T04:59:21Z
dc.date.available2020-03-26T04:59:21Z
dc.date.issued2020-01-10en_US
dc.description.abstract© 2019 American Chemical Society. In May 2019, the Wellcome Centre for Anti-Infectives Research (WCAIR) at the University of Dundee, UK, held an international conference with the aim of discussing some key questions around discovering new medicines for infectious diseases and a particular focus on diseases affecting Low and Middle Income Countries. There is an urgent need for new drugs to treat most infectious diseases. We were keen to see if there were lessons that we could learn across different disease areas and between the preclinical and clinical phases with the aim of exploring how we can improve and speed up the drug discovery, translational, and clinical development processes. We started with an introductory session on the current situation and then worked backward from clinical development to combination therapy, pharmacokinetic/pharmacodynamic (PK/PD) studies, drug discovery pathways, and new starting points and targets. This Viewpoint aims to capture some of the learnings.en_US
dc.identifier.citationACS Infectious Diseases. Vol.6, No.1 (2020), 3-13en_US
dc.identifier.doi10.1021/acsinfecdis.9b00371en_US
dc.identifier.issn23738227en_US
dc.identifier.other2-s2.0-85076754483en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/53782
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85076754483&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleSetting Our Sights on Infectious Diseasesen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85076754483&origin=inwarden_US

Files

Collections

Scopus 2020